| abstract |
It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a "ligand moiety") through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a "metallodrug" or "metallotherapeutic." The metal binding domain of metallodrugs typically catalyzes oxido- reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target. |